Elicit: Real-Time Kidney Damage Markers (public)

What are the most effective real-time markers of kidney cell damage?

NGAL, [TIMP‑2]·[IGFBP7], and KIM-1 are the most effective real-time markers of kidney cell damage, showing high diagnostic accuracy when measured at appropriate time windows and achieving superior performance when combined in multi-marker panels.

Abstract

Real‐time markers for kidney cell damage most consistently report high diagnostic accuracy when measured in the appropriate clinical context and time window. Urinary neutrophil gelatinase‐associated lipocalin (NGAL) rises within 2–6 hours after injury, with studies reporting area under the curve (AUC) values up to 0.91, sensitivities of 84–100%, and specificities as high as 99.5%. Urinary [TIMP‑2]·[IGFBP7] is typically measured at 6–12 hours post‐injury and shows AUC values ranging from 0.70 to 0.94, with reported sensitivities of 42–96% and specificities up to 95%. Urinary kidney injury molecule‑1 (KIM‑1) measured at 12–24 hours post‐insult yields moderate performance (AUC 0.66–0.84) with sensitivities between 75.9% and 91.6% and specificities up to 95.2%.

When combined in multi‐marker panels, these biomarkers often achieve superior performance. For example, panels including NGAL, [TIMP‑2]·[IGFBP7], and cystatin C have produced AUC values as high as 0.98, while combinations with additional markers have reached similar levels of discrimination. These findings, drawn from a diverse set of populations and clinical settings—ranging from cardiac surgery and intensive care to emergency presentations—support the use of NGAL, [TIMP‑2]·[IGFBP7], and KIM‑1 as effective real‐time indicators of kidney cell damage.

Methods

We analyzed 40 sources from an initial pool of 999, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Paper search

Using your research question “What are the most effective real-time markers of kidney cell damage?”, we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 999 papers most relevant to the query.

Screening

We screened in sources based on their abstracts that met these criteria:

Real-time Biomarker Detection: Does this study evaluate biomarkers that can detect kidney cell damage in real-time or near real-time (within 24 hours maximum)?
Human Participants: Does this study involve human participants with actual or potential kidney cell damage?
Diagnostic Performance Assessment: Does this study assess diagnostic performance metrics (such as sensitivity, specificity, positive/negative predictive values, AUC, or diagnostic accuracy)?
Appropriate Study Design: Is this study a prospective cohort study, cross-sectional diagnostic accuracy study, randomized controlled trial, systematic review, or meta-analysis?
Comparative Assessment: Does this study compare novel biomarkers to established reference standards or other biomarkers?
Clinical Study Setting: Is this study conducted in a clinical setting (not exclusively animal studies, in vitro studies, or cell culture studies)?
Primary Research Quality: Is this study a primary research study or high-quality secondary research (not a case report, case series, editorial, or opinion piece)?
Clinical Utility Assessment: Does this study assess the diagnostic performance or clinical utility of biomarkers (not just measure biomarker levels without performance evaluation)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Study design:

Specify the exact type of study design used. Look in the methods section for precise description. Possible types include:

Cross-sectional study
Prospective multicenter study
Case-control study
Cohort study

If multiple design elements are present, list all. If design is not clearly stated, write “design not clearly specified”.

Participant characteristics:

Extract the following details:

Total number of participants
Patient population (e.g., critically ill patients, cardiac surgery patients)
Age range or mean age
Gender distribution
Specific inclusion/exclusion criteria

If any of these details are missing, note “not reported”. Use exact numbers and percentages from the text. If ranges are provided, include both minimum and maximum values.

Biomarkers investigated:

List ALL biomarkers examined in the study for detecting kidney cell damage. Include:

Full name of biomarker
Source of biomarker (e.g., urine, serum)
Measurement method (if specified)

If multiple biomarkers were studied, list them in order of appearance in the text. If a specific combination or interaction of biomarkers was studied (e.g., [TIMP-2]·[IGFBP7]), note this explicitly.

Biomarker performance metrics:

Extract quantitative performance data for biomarkers, specifically:

Area Under the Curve (AUC)
Sensitivity
Specificity
Confidence intervals (if reported)
Cutoff values used

Ensure you capture the specific context of performance (e.g., detecting early vs. late stage kidney injury). If multiple time points or conditions are reported, extract data for each.

Primary outcome definition:

Describe how acute kidney injury (AKI) was defined and diagnosed in the study. Look for:

Specific diagnostic criteria used
Staging system (e.g., KDIGO, RIFLE)
Specific thresholds (e.g., 50% increase in serum creatinine)
Method of clinical adjudication

If multiple definitions or methods are used, list all. If the definition is not clearly stated, write “outcome definition not clearly specified”.

Results

Characteristics of Included Studies

Study	Study Population	Biomarkers Evaluated	AKI Definition	Primary Outcome
Bihorac et al., 2014	Critically ill patients (n=420)	Urinary [TIMP-2]·[IGFBP7]	No mention found	Prediction of moderate to severe acute kidney injury (AKI) within 12h
Piedrafita et al., 2022	Cardiac surgery (n=1170), intensive care unit (ICU) (n=1569)	Urinary peptide signature, neutrophil gelatinase-associated lipocalin (NGAL), calprotectin, [TIMP-2]/[IGFBP7]	Kidney Disease: Improving Global Outcomes (KDIGO) 2012	Early AKI prediction (7-day KDIGO)
Sun et al., 2024	Critically ill patients (n=417+164)	12 urinary biomarkers, U-AKIpredTM (alpha-1-microglobulin, liver-type fatty acid-binding protein (L-FABP), IGFBP7)	KDIGO	AKI within 12h of panel measurement
Desai et al., 2022	Hospitalized patients (systematic review)	Beta-2 microglobulin (B2M), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), L-FABP, NGAL, [TIMP-2]*[IGFBP7]	No mention found	Early detection of drug-induced AKI
Han et al., 2008	Acute/chronic kidney disease, pediatric cardiopulmonary bypass (CPB)	Urinary matrix metalloproteinase-9 (MMP-9), N-acetyl-beta-D-glucosaminidase (NAG), KIM-1	>50% serum creatinine (SCr) increase in 48h	Early AKI diagnosis
Jarvis, 2011	ICU patients (n=529)	Gamma-glutamyl transferase (GGT), alkaline phosphatase (AP), NGAL, cystatin C (CysC), KIM-1, IL-18	No mention found	Diagnosis/prediction of AKI, dialysis, death
Koyner et al., 2010	Cardiac surgery (n=123)	Urinary NGAL, CysC, KIM-1, hepatocyte growth factor (HGF), pi-glutathione S-transferase (π-GST), alpha-glutathione S-transferase (α-GST)	No mention found	Early detection and prognosis of AKI
Pan et al., 2022	Adults >18, mixed settings (n=38,725)	NGAL (urine/serum), KIM-1, L-FABP, IL-18, [TIMP-2]·[IGFBP7]	KDIGO, Acute Kidney Injury Network (AKIN), Risk, Injury, Failure, Loss, End-stage kidney disease (RIFLE)	Predictive performance of biomarkers for AKI
Nickolas et al., 2012	Emergency department (ED) patients (n=1,635)	Urinary NGAL, KIM-1, L-FABP, IL-18, CysC	No mention found	Diagnostic/prognostic value of biomarkers
Dong et al., 2017	Pediatric cardiac surgery (n=150)	Urinary NGAL, IL-18, L-FABP, KIM-1, [TIMP-2], IGFBP7	KDIGO (≥50% SCr increase)	Sequential biomarker elevation for AKI

Summary of Study Characteristics:

Most commonly evaluated biomarkers:
- Neutrophil gelatinase-associated lipocalin (NGAL):29 studies
- Kidney injury molecule-1 (KIM-1):21 studies
- [TIMP-2]·[IGFBP7]:12 studies
- Interleukin-18 (IL-18):11 studies
- Liver-type fatty acid-binding protein (L-FABP):8 studies
- Cystatin C (CysC):14 studies
- Other biomarkers(e.g., NAG, B2M, SCr/creatinine, albumin, clusterin, GSTs, HGF, microRNAs, etc.): each evaluated in 1–4 studies
Study populations:
- Critically ill:7 studies
- Intensive care unit (ICU):6 studies
- Cardiac surgery:7 studies
- Emergency department (ED)/emergency room (ER):6 studies
- Pediatric:2 studies
- Transplant:3 studies
- Drug-induced/nephrotoxic settings:5 studies
- Hospitalized (general):2 studies
- Other populations(diabetes, heart failure, poisoning, snake envenoming, neonates, abdominal aortic aneurysm (AAA) surgery, at-risk adults, etc.): 1 study each
AKI definitions used:
- KDIGO:15 studies
- AKIN:8 studies
- RIFLE:3 studies
- Serum creatinine (SCr) increase (not otherwise specified):3 studies
- GFR-based:1 study
- No mention found of a clearly specified AKI definition:13 studies
Primary outcomes:
- Early AKI detection/diagnosis:19 studies
- Prediction (including risk stratification, prediction of AKI, or progression):13 studies
- Prognosis (renal recovery, adverse events, delayed graft function):6 studies
- Drug-induced AKI detection:5 studies
- Other outcomes(biomarker timing/performance, diabetic nephropathy, etc.): 3 studies
Heterogeneity:There was no consistent AKI definition across all studies. Several studies evaluated multiple biomarkers or included multiple populations or outcomes.

Individual Biomarker Performance

Biomarker	Area Under the Curve (AUC) Range	Sensitivity Range	Specificity Range
[TIMP-2]·[IGFBP7]	0.70–0.94	42–96%	50–95%
NGAL (urine)	0.62–0.91	55–100%	64–99.5%
KIM-1 (urine)	0.66–0.84	75.9–91.6%	61.8–95.2%
Cystatin C (urine/plasma)	0.68–0.88	71–79.3%	74.2–92%
Albumin (urine)	0.44–0.94	No mention found	No mention found
IL-18 (urine)	0.72–0.94	75–85%	63–73%
Midkine (urine)	0.88–0.96	87–97%	85–90%
Peptide signature (urine)	0.78–0.79	No mention found	No mention found
Clusterin (urine)	0.81	No mention found	No mention found
Urine microscopy/sediment	0.79–0.865	6–30%	91–98.6%

Combined Biomarker Performance

Several studies reported that combinations of biomarkers outperformed individual markers. Key findings from these studies include:

Dong et al., 2017: Combination of NGAL, IL-18, and [TIMP-2] yielded an AUC of 0.973 at 12 hours post-cardiopulmonary bypass, higher than any single marker.
Che et al., 2010: Combination of five biomarkers (cystatin C, NGAL, IL-18, retinol-binding protein, NAG) achieved an AUC of 0.98.
Gupta et al., 2025: Combination of [TIMP-2]·[IGFBP7], NGAL, and cystatin C yielded an AUC of 0.92, which improved to 0.94 when clinical risk factors were included.
Elmedany et al., 2017: Combination of NGAL, KIM-1, and urine sediment yielded an AUC of 0.906.

Summary:

In the studies where this was evaluated, multi-marker panels and combinations were reported to outperform single biomarkers, particularly for early detection and risk stratification.
The most effective combinations typically included [TIMP-2]·[IGFBP7] and NGAL, sometimes with cystatin C or clinical variables.

Timing of Detection and Clinical Context

Biomarker/Combination	Optimal Detection Window	Clinical Context	Performance Metrics
NGAL (urine)	2–6 hours post-injury	Pediatric cardiopulmonary bypass, sepsis, ICU	AUC >0.9 (early), Sensitivity 84–100%, Specificity 80–99.5%
[TIMP-2]·[IGFBP7]	6–12 hours post-injury	ICU, cardiac surgery, ED	AUC 0.70–0.94, Sensitivity 89–96%, Specificity 50–95%
KIM-1 (urine)	12–24 hours post-injury	Drug-induced, contrast nephropathy	AUC 0.66–0.84, Sensitivity 75.9–91.6%, Specificity 61.8–95.2%
Multi-marker panels	6–24 hours post-injury	Cardiac surgery, ICU, diverse AKI	AUC 0.906–0.98
Urine sediment	2–48 hours post-injury	Cardiac surgery, ICU	AUC 0.79–0.865, Specificity 91–98.6%

Factors Affecting Biomarker Performance

Patient population: Performance varied by clinical context, including ICU, surgery, sepsis, drug-induced injury, pediatric, oncology, and neonates.
Comorbidities: Some markers, such as [TIMP-2]·[IGFBP7], were reported to be robust across comorbidities (chronic kidney disease, congestive heart failure, diabetes), while others may be confounded.
Timing: Early sampling was critical. NGAL typically rose first, followed by [TIMP-2]·[IGFBP7], KIM-1, and others.
AKI definition: Variability in AKI definitions (KDIGO, AKIN, RIFLE, expert adjudication) affected comparability across studies.
Analytical methods: Differences in assay platforms, normalization (e.g., to creatinine), and cutoff values impacted reported performance.
Clinical variables: Integration with clinical risk factors and scoring systems improved predictive accuracy.